Can Probiotics Support Lung Health Through the Gut–Lung Axis?

What Does the Gut Have to Do With the Lungs?

The intestine and lungs may appear to be completely separate organs.

But immunologically and metabolically, they communicate continuously.

This communication network is known as the gut–lung axis.

The gut microbiome can influence pulmonary immunity through microbial metabolites and immune signals. Recent reviews describe gut microbiota as important regulators of pulmonary immune responses through metabolites such as short-chain fatty acids, tryptophan derivatives and other microbial products. (PubMed⁠)

Because probiotics can modify aspects of intestinal microbial ecology, researchers have begun asking whether they might support lung health indirectly.

The answer depends heavily on what we mean by “support.”

There is convincing evidence that intestinal microbes influence immunity.

There is growing evidence that probiotics can modify immune responses in selected respiratory diseases.

But there is much less evidence that probiotic supplements can treat established chronic structural lung diseases such as pulmonary fibrosis.

How Does the Gut Communicate With the Lungs?

The major pathways include:

• microbial metabolites

• circulating immune cells

• cytokines

• intestinal-barrier signaling

• bone marrow immune programming

The gut–lung axis is therefore primarily an immune-metabolic network.

SCFAs: One of the Most Important Connections

Dietary fiber is fermented by intestinal microorganisms to generate:

• acetate

• propionate

• butyrate

These SCFAs can enter systemic circulation.

They influence immune cells through G-protein-coupled receptors and epigenetic effects such as HDAC inhibition.

A 2025 review found that dietary fiber and SCFAs can modify pulmonary immune responses and influence immune-cell recruitment to the lung. (PubMed⁠)

Probiotic organisms may potentially contribute indirectly by supporting microbial networks capable of SCFA production.

The Bone Marrow Connection

The gut can influence the lung even before immune cells reach the respiratory tract.

Microbial metabolites can modify hematopoietic cells in bone marrow.

Those cells can subsequently migrate to the lungs.

This helps explain why a dietary or intestinal signal can influence respiratory immunity without bacteria physically moving from gut to lung. (PubMed⁠)

Probiotics and Intestinal Barrier Function

Certain probiotics may support:

• mucus production

• epithelial integrity

• tight junctions

A stronger intestinal barrier may reduce inappropriate systemic exposure to microbial products.

This could theoretically reduce systemic inflammatory signaling.

Probiotics and LPS

Lipopolysaccharide can activate:

TLR4 → NF-κB

and stimulate inflammatory cytokine pathways.

If probiotics improve intestinal microbial ecology and barrier integrity, systemic LPS exposure might potentially decrease.

This remains a mechanistic hypothesis in many chronic lung diseases.

Treg and Th17 Regulation

Gut microbes affect regulatory T cells and Th17 cells.

A balanced immune response requires both effective defense and adequate immune tolerance.

Excessive Th17 signaling has been implicated in several respiratory inflammatory disorders.

Microbiome-dependent modulation of the Treg–Th17 axis is therefore an important area of gut–lung research.

Macrophages

Macrophages are central to respiratory immunity.

Microbial metabolites may influence whether macrophages adopt more inflammatory, repair-oriented or tissue-remodeling phenotypes.

In pulmonary fibrosis, inappropriate macrophage signaling can contribute to fibroblast activation.

Probiotics and Respiratory Infection

The strongest probiotic evidence in respiratory medicine historically relates more to:

• respiratory infections

• immune modulation

• selected airway inflammatory disorders

than to structural fibrotic lung diseases.

This reinforces an important point:

“lung health” encompasses many biological processes and many different diseases.

An intervention that reduces respiratory infection frequency does not automatically treat pulmonary fibrosis.

Asthma and the Gut–Lung Axis

Early-life microbiome composition has been repeatedly associated with immune development and asthma risk.

This has contributed strongly to the overall gut–lung hypothesis.

But asthma is immunologically very different from IPF.

Evidence from asthma should not be automatically extrapolated to fibrosis.

COPD and the Gut Microbiome

Gut dysbiosis has also been described in COPD.

Potential contributors include:

• smoking

• systemic inflammation

• medications

• reduced activity

• diet

Probiotic strategies remain experimental.

Acute Lung Injury and ARDS

Animal models have shown substantial bidirectional communication between the intestine and lungs during critical illness.

Severe lung injury can disrupt intestinal microbial communities and barrier integrity.

This demonstrates that the gut–lung axis is genuinely bidirectional.

Probiotics in Pulmonary Fibrosis

Pulmonary fibrosis provides perhaps one of the most mechanistically intriguing areas.

A 2025 Lactiplantibacillus study found reduced experimental fibrosis accompanied by microbiome remodeling, increased PEA and suppression of TGF-β1/Smad2/3 signaling. (PubMed⁠)

This provides proof of concept in animals.

It is not proof of efficacy in humans.

Diet, Probiotics and Cross-Feeding

Probiotic effects depend partly on diet.

Microorganisms require substrates.

For example, one organism may produce lactate that another bacterium converts into butyrate.

This interaction is known as cross-feeding.

Therefore, taking probiotics while consuming a diet that does not support microbial fermentation may produce very different results from combining probiotics with appropriate dietary substrates.

Why Fiber Matters

Dietary fiber can increase substrates available for SCFA-producing bacteria.

A 2026 systematic review of 80 controlled dietary trials found that dietary interventions can alter gut microbial taxa and metabolic markers. Mediterranean, high-fiber, plant-rich and high-polyphenol dietary patterns were frequently associated with increased SCFA- or lactic-acid-producing organisms or reduced opportunistic organisms. (PubMed⁠)

This suggests that diet may sometimes be a more powerful microbiome intervention than probiotic supplementation alone.

Not Everyone Needs More Fermentation

A universal recommendation for more fiber or probiotics is inappropriate.

Some people have:

• SIBO

• significant bloating

• intestinal dysmotility

• systemic sclerosis

• altered bowel habits

In these individuals, large amounts of fermentable substrates may initially worsen symptoms.

Probiotics and the Oral–Gut–Lung Network

Respiratory microbial ecology is influenced not only by the gut.

The oral cavity is a major source of microorganisms entering the lower respiratory tract through microaspiration.

Future respiratory microbiome research may increasingly consider:

oral microbiome + lung microbiome + gut microbiome

as an interconnected system.

Can Probiotics Prevent Lung Disease?

There is insufficient evidence to recommend probiotics broadly for prevention of chronic lung disease.

The effectiveness likely depends on:

• age

• disease

• microbial baseline

• probiotic strain

• diet

• medications

• environmental exposures

Can Probiotics Improve Pulmonary Function?

No general probiotic has been proven to meaningfully improve pulmonary function across chronic respiratory diseases.

Studies must be interpreted disease by disease.

Can Probiotics Reduce Lung Inflammation?

Selected probiotics can modify systemic and respiratory inflammatory signals in experimental and some clinical settings.

However, “reducing inflammation” is not the same as improving long-term disease outcomes.

This distinction is especially important in pulmonary fibrosis.

Can Probiotics Improve Lung Fibrosis?

There is currently no adequate human evidence showing that probiotics reverse established lung fibrosis.

The data remain predominantly preclinical. (PubMed⁠)

Probiotics and Immunosuppressed Patients

People with autoimmune ILD may receive substantial immunosuppression.

In this population, probiotic decisions should be individualized.

Rare invasive infections associated with probiotic organisms have occurred in severely vulnerable patients.

What About Fermented Foods?

Fermented foods can contain living microorganisms and microbial metabolites.

But they are not equivalent to standardized probiotic supplements.

Their microbial composition varies substantially.

They may fit within a healthy diet for many individuals but should not be presented as pulmonary treatment.

Functional and Integrative Medicine Perspective

The gut–lung axis provides a scientifically plausible framework for incorporating gastrointestinal and nutritional health into respiratory care.

An integrative approach may assess:

• dietary diversity

• gastrointestinal symptoms

• bowel function

• reflux

• nutritional status

• metabolic health

Probiotics may be considered selectively.

But treatment should remain disease-specific.

What We Know

We know that:

• gut microbial metabolites influence pulmonary immunity

• diet modifies intestinal microbial ecology

• SCFAs influence immune responses in the lungs

• probiotics can modify gut ecology and immune signaling

• selected probiotic interventions have shown pulmonary benefits experimentally

(PubMed⁠)

What We Do Not Know

We do not know:

• the optimal probiotic for general lung health

• which strains work for which respiratory disease

• the optimal duration

• whether baseline microbiome testing can identify responders

• whether routine supplementation improves long-term respiratory outcomes

Frequently Asked Questions

Are probiotics good for the lungs?

They may influence lung immunity through the gut–lung axis, but benefits depend on the specific probiotic, disease and clinical context.

Which probiotic is best for lung health?

No single probiotic has been established as the best probiotic for respiratory health.

Can gut bacteria affect the lungs?

Yes. Microbial metabolites and immune signals from the intestine can influence pulmonary immunity.

Can probiotics increase SCFAs?

Certain probiotic ecosystems may support SCFA production, especially when appropriate dietary substrates are available.

Are probiotics a replacement for respiratory medication?

No.

Conclusion

The scientific basis of the gut–lung axis is increasingly strong.

Gut microorganisms produce metabolites capable of influencing:

• pulmonary immune cells

• epithelial responses

• bone marrow immune programming

• systemic inflammation

Probiotics may potentially alter some of these pathways.

But the phrase “probiotics support lung health” should not be interpreted as evidence that a probiotic supplement treats all lung diseases.

Different diseases have fundamentally different biology.

For pulmonary fibrosis in particular, probiotic research is promising but remains experimental.

The future may lie in precision approaches that identify the right:

microorganism + dietary substrate + microbial metabolite + patient phenotype.

That would represent a much more sophisticated strategy than simply recommending a generic probiotic for everyone with lung disease.

About Dr. Samar Shadly

Dr. Samar Shadly is a Consultant Pulmonologist and Certified Functional Medicine Practitioner, with advanced subspecialty training in interstitial lung disease, pulmonary fibrosis, pulmonary hypertension, and lung transplantation, together with expertise in functional and integrative medicine.

Her approach combines evidence-based pulmonary medicine with a broader assessment of factors that may influence a patient’s overall health, including nutrition, gastrointestinal health, the gut microbiome, metabolic health, lifestyle, and relevant environmental exposures.

A particular focus of her work is the emerging field of Integrative and Functional Pulmonology, especially in pulmonary fibrosis and autoimmune-associated interstitial lung disease. Her goal is to bridge conventional respiratory medicine with scientifically grounded integrative strategies, while clearly distinguishing established clinical evidence from promising but still experimental research.

Living with Pulmonary Fibrosis or Interstitial Lung Disease?

If you are looking for a more comprehensive assessment that combines specialist pulmonary expertise with a functional and integrative perspective, you can explore whether this approach may be appropriate for your individual condition.

To learn more about consultation options or request an assessment, contact us through the consultation page or WhatsApp.

Integrative care is intended to complement—not replace—evidence-based pulmonary treatment and should always be individualized according to the diagnosis and clinical situation.